Truist raised the firm’s price target on Amedisys (AMED) to $101 from $97 and keeps a Hold rating on the shares. The company’s pending deal with UnitedHealth Group/Optum (UNH) at $101 per share is a nice complement to UnitedHealth’s already strong home-based care platform, the analyst tells investors in a research note. The firm adds that it also remains bullish on underlying trends at standalone Option Care Health (OPCH) as Amedisys deal terminates that merger agreement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMED:
- Amedisys price target raised to $101 from $88 at Barclays
- UNH Gains Slightly after Announcing New Merger Deal
- Option Care Health confirms termination of merger agreement with Amedisys
- Amedisys to combine with Optum in all-cash deal at $101 per share
- Amedisys and Optum to Combine, Advancing Value-Based Care for Patients